Zobrazeno 1 - 10
of 40
pro vyhledávání: '"S. Arbuck"'
Autor:
Daniel J. Sargent, Lalitha K. Shankar, P. Therasse, S. Arbuck, Denis Lacombe, Robert M. Kaplan, Lawrence H. Schwartz, Jan Bogaerts, Larry Rubinstein, Jaap Verweij, Elizabeth Eisenhauer, Robert Ford, S. Gwyther, Lori E. Dodd, Janet Dancey, Margaret M. Mooney
Publikováno v:
European Journal of Cancer. 45:228-247
Background Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890b92e312408c053f6a4d334b0d23c2
https://doi.org/10.1016/j.ejca.2008.10.026
https://doi.org/10.1016/j.ejca.2008.10.026
Publikováno v:
Scopus-Elsevier
Intraperitoneal (i.p.) chemotherapy is being investigated as an adjunct to surgery to kill residual cancer cells, inhibit cancer cell seeding, local recurrence, and metastases for ovarian, gastric, and colon cancers. In this report, the therapeutic e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c875549a6dfa9ae2b58cf818b3c9bb4
https://doi.org/10.1089/sct.1990.6.193
https://doi.org/10.1089/sct.1990.6.193
Publikováno v:
Progress in Anti-Cancer Chemotherapy ISBN: 9782287596926
Most chemotherapeutic agents used today were identified by empirically screening natural products or synthetic compounds for cytotoxic potency in vitro against murine and/or human cancer cell lines and in vivo against rodent tumor models. [1] The maj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dc1c99e21f4ff777cf0fbf08cd39c53
https://doi.org/10.1007/978-2-8178-0920-5_6
https://doi.org/10.1007/978-2-8178-0920-5_6
Autor:
H S, Friedman, T, Kerby, S, Fields, J E, Zilisch, D, Graden, R E, McLendon, P J, Houghton, S, Arbuck, I, Cokgor, A H, Friedman
Publikováno v:
Cancer. 85(5)
Topotecan activity was evaluated for the treatment of malignant glioma.Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan [AU: Please verify all dosages here and throughout text.]at a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ac7a45b38ac2a7737cafd698e208abc
https://pubmed.ncbi.nlm.nih.gov/10091802
https://pubmed.ncbi.nlm.nih.gov/10091802
Autor:
M, Beran, H, Kantarjian, S, O'Brien, C, Koller, M, al-Bitar, S, Arbuck, S, Pierce, M, Moore, J L, Abbruzzese, M, Andreeff, M, Keating, E, Estey
Publikováno v:
Blood. 88(7)
The aim of this study was to evaluate the activity of topotecan in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Forty-seven patients with a diagnosis of MDS (n = 22) or CMML (n = 25) were treated. The media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ce51b3be7e3ec24765b02fe1cd3cf1e
https://pubmed.ncbi.nlm.nih.gov/8839838
https://pubmed.ncbi.nlm.nih.gov/8839838
Autor:
Raymond Alexanian, M. Huber, S. Arbuck, K. B. Delasalle, Meletios A. Dimopoulos, R. Luckett, Donna M. Weber
Publikováno v:
Scopus-Elsevier
Summary Background The treatment of multiple myeloma remains unsatisfactory and new active agents are needed. Paclitaxel is effective against a variety of solid tumors and we assessed the utility against multiple myeloma. Patients and methods From Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ff13545e0658a0631256678cb48658
https://pubmed.ncbi.nlm.nih.gov/7826909
https://pubmed.ncbi.nlm.nih.gov/7826909
Autor:
Robert Ford, P. Therasse, Elizabeth Eisenhauer, Robert M. Kaplan, Lawrence H. Schwartz, S. Gwyther, Jan Bogaerts, Daniel J. Sargent, Janet Dancey, Lalitha K. Shankar, M. Mooney, L. Rubenstein, Jaap Verweij, S. Arbuck, Denis Lacombe
Publikováno v:
European Journal of Cancer Supplements. 6:13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2de7a92aa71d012ccc9180bbdb02a8fb
https://doi.org/10.1016/s1359-6349(08)71964-5
https://doi.org/10.1016/s1359-6349(08)71964-5
Publikováno v:
Journal of Pediatric Hematology/Oncology. 21:326
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b60fa75981c8e93a6cefd8d01300439
https://doi.org/10.1097/00043426-199907000-00089
https://doi.org/10.1097/00043426-199907000-00089
Autor:
A. Chachoua, Joan Sorich, C. Wasserheit, B. Taubes, Howard S. Hochster, S. Arbuck, A. Friedberg, J. Speyer
Publikováno v:
European Journal of Cancer. 33:S250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4405013efb7e9463bd29c64bb7f6bd78
https://doi.org/10.1016/s0959-8049(97)86041-8
https://doi.org/10.1016/s0959-8049(97)86041-8
Autor:
P J, Creaven, S, Madajewicz, L, Pendyala, A, Mittelman, E, Pontes, M, Spaulding, S, Arbuck, J, Solomon
Publikováno v:
Cancer treatment reports. 67(9)
cis-Dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP), a second-generation platinum complex with little or no nephrotoxicity in preclinical studies, has undergone phase I clinical testing and initial pharmacokinetic evaluation in 26 pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d4700b9628676849aeac1d9943e72245
https://pubmed.ncbi.nlm.nih.gov/6883356
https://pubmed.ncbi.nlm.nih.gov/6883356